Nandi Moujhuri, Mahata Anurupa, Mallick Indranil, Achari Rimpa, Chatterjee Sanjoy
Radiation Oncology, Senior registrar, Apollo Gleneagles Hospital Limited, KOLKATA, India E-mail :
Asian Pac J Cancer Prev. 2014;15(6):2505-10. doi: 10.7314/apjcp.2014.15.6.2505.
The standard radiotherapy (RT) fractionation practiced in India and worldwide is 50 Gy in 25 fractions over 5 weeks to the chest wall or whole breast followed by tumour bed boost in case of breast conservation (BCS). A body of validated data exists regarding hypofractionation in breast cancer. We here report initial results for 135 patients treated at our center with the START-B type of fractionation.
From May 2011 till July 2012, women with all stages of breast cancer (excluding metastatic), who had undergone BCS or mastectomy were planned for 40 Gy in 15 fractions over 3 weeks to chest wall/whole breast and supraclavicular fossa (where indicated) followed by tumour bed boost in BCS patients. Planning was done using Casebow's technique. The primary end point was to assess the acute toxicity and the cosmetic outcomes. Using cosmetic scales; patients were assessed during radiotherapy and at subsequent follow up visits with the radiation oncologist.
Of the 135 patients, 62 had undergone BCS and 73 mastectomy. Median age of the population was 52 years. Some 80% were T1 and T2 tumours in BCS whereas most patients in mastectomy group were T3 and T4 tumours (60%). 45% were node negative in BCS group whilst it was 23% in the mastectomy group. Average NPI scores were 3.9 and 4.9, respectively. Most frequently reported histopathology report was infiltrating ductal carcinoma (87%), grade III being most common (58%), and 69% were ER positive tumours, and 30% were Her 2 Neu positive. Triple negative tumours accounted for 13% and their mean age was young (43 yrs.) The maximum acute skin toxicity at the end of treatment was Grade 1 in 94% of the mastectomy group patients and 71% in BCS patients. Grade 2 toxicity was 6% in mast group and 23% in BCS group. Grade 3 was 6% in BCS group, no grade 3 toxicity in mastectomy patients and there was no grade 4 skin toxicity in any case. Post RT at 1 month; 39% of BCS patients had persisting Grade I skin reaction which was only 2% in mastectomy patients. At 3 months post RT, 18% patients had persisting hyperpigmentation. At 6 months 8% patients had persisting erythema in the BCS group only. Some 3% BCS and 8% mastectomy patients had lymph edema till the date of evaluation. Cosmetic outcome in BCS patients remained good to excellent 6 months post surgery and radiotherapy. 1 patient of BCS and 3 patients of mast had developed metastatic disease at the time of evaluation.
Hypofractionated RT is well tolerated in Indian population with reduced acute skin toxicity and good cosmetic outcome. Regimens such as these should be encouraged in other centers to increase machine output time. The study is on-going to assess long term results.
印度及全球采用的标准放疗分割方案是,对胸壁或全乳进行5周25次分割,总剂量50 Gy,保乳手术(BCS)患者后续对瘤床进行加量照射。关于乳腺癌低分割放疗已有大量经过验证的数据。我们在此报告在本中心接受START - B型分割放疗的135例患者的初步结果。
2011年5月至2012年7月,对所有分期(不包括转移性)的乳腺癌女性患者,在接受保乳手术或乳房切除术后,计划对胸壁/全乳及锁骨上窝(如有指征)进行3周15次分割、总剂量40 Gy的放疗,保乳手术患者后续对瘤床进行加量照射。采用Casebow技术进行放疗计划制定。主要终点是评估急性毒性和美容效果。使用美容量表,在放疗期间及随后与放疗肿瘤学家的随访中对患者进行评估。
135例患者中,62例行保乳手术,73例行乳房切除术。患者中位年龄为52岁。保乳手术患者中约80%为T1和T2期肿瘤,而乳房切除组大多数患者为T3和T4期肿瘤(60%)。保乳手术组45%患者淋巴结阴性,乳房切除组为23%。平均NPI评分分别为3.9和4.9。最常见的组织病理学报告为浸润性导管癌(87%),III级最为常见(58%),69%为雌激素受体阳性肿瘤,30%为Her 2 Neu阳性。三阴性肿瘤占13%,其平均年龄较轻(43岁)。治疗结束时,乳房切除组94%患者的最大急性皮肤毒性为1级,保乳手术患者为71%。2级毒性在乳房切除组为6%,保乳手术组为23%。3级毒性在保乳手术组为6%,乳房切除患者无3级毒性,且在任何情况下均无4级皮肤毒性。放疗后1个月,39%的保乳手术患者仍有1级皮肤反应,乳房切除患者仅为2%。放疗后3个月,18%的患者仍有色素沉着。放疗后6个月,仅保乳手术组8%的患者仍有红斑。至评估时,约3%的保乳手术患者和8%的乳房切除患者有淋巴水肿。保乳手术患者在手术和放疗后6个月的美容效果保持良好至极佳。评估时,1例保乳手术患者和3例乳房切除患者发生了转移性疾病。
低分割放疗在印度人群中耐受性良好,急性皮肤毒性降低,美容效果良好。其他中心应鼓励采用此类方案以增加机器输出时间。该研究正在进行以评估长期结果。